Verastem's G12D Drug Shows Promise in Pancreatic Cancer, Shares Undervalued, RBC Says

MT Newswires Live10-16

Verastem's (VSTM) G12D drug showed promising efficacy in pancreatic cancer, while its shares remain undervalued, RBC Capital Markets said in a note Thursday.

The analysts said the company presented new research and development results for its G12D drug at an R&D day. The drug appears to be active, with early signs that it could deliver strong efficacy in treating pancreatic cancer.

More data is needed to determine whether the drug offers meaningful advantages over competing G12D treatments. However, RBC believes the company has outlined a strategy to target a niche in the US market and that its shares do not fully reflect the potential value of its pipeline and Av-Fak business.

The analysts said VS-7375's efficacy data were encouraging, with a confirmed response rate of 41% in pancreatic cancer. However, they cautioned that comparisons with competing drugs are complicated by small patient numbers and differences between trial populations. RBC also noted that the drug's tolerability profile lagged that of zoldon, although it viewed the safety profile as manageable.

RBC raised its price target on Verastem to $19 from $14, with an outperform rating.

The company's shares were up nearly 6% in Thursday afternoon trading.

Price: 8.16, Change: +0.45, Percent Change: +5.84

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2675153916?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-10-16 00:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2675153916","market":"sg","top_or_hot":-1,"title":"Verastem's G12D Drug Shows Promise in Pancreatic Cancer, Shares Undervalued, RBC Says","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/VSTM\">Verastem</a>'s (VSTM) G12D drug showed promising efficacy in pancreatic cancer, while its shares remain undervalued, RBC Capital Markets said in a note Thursday.</p><p>The analysts said the company presented new research and development results for its G12D drug at an R&amp;D day. The drug appears to be active, with early signs that it could deliver strong efficacy in treating pancreatic cancer.</p><p>More data is needed to determine whether the drug offers meaningful advantages over competing G12D treatments. However, RBC believes the company has outlined a strategy to target a niche in the US market and that its shares do not fully reflect the potential value of its pipeline and Av-Fak business.</p><p>The analysts said VS-7375's efficacy data were encouraging, with a confirmed response rate of 41% in pancreatic cancer. However, they cautioned that comparisons with competing drugs are complicated by small patient numbers and differences between trial populations. RBC also noted that the drug's tolerability profile lagged that of zoldon, although it viewed the safety profile as manageable.</p><p>RBC raised its price target on Verastem to $19 from $14, with an outperform rating.</p><p>The company's shares were up nearly 6% in Thursday afternoon trading.</p><p>Price: 8.16, Change: +0.45, Percent Change: +5.84</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Verastem's G12D Drug Shows Promise in Pancreatic Cancer, Shares Undervalued, RBC Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVerastem's G12D Drug Shows Promise in Pancreatic Cancer, Shares Undervalued, RBC Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-10-16 00:27</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/VSTM\">Verastem</a>'s (VSTM) G12D drug showed promising efficacy in pancreatic cancer, while its shares remain undervalued, RBC Capital Markets said in a note Thursday.</p><p>The analysts said the company presented new research and development results for its G12D drug at an R&amp;D day. The drug appears to be active, with early signs that it could deliver strong efficacy in treating pancreatic cancer.</p><p>More data is needed to determine whether the drug offers meaningful advantages over competing G12D treatments. However, RBC believes the company has outlined a strategy to target a niche in the US market and that its shares do not fully reflect the potential value of its pipeline and Av-Fak business.</p><p>The analysts said VS-7375's efficacy data were encouraging, with a confirmed response rate of 41% in pancreatic cancer. However, they cautioned that comparisons with competing drugs are complicated by small patient numbers and differences between trial populations. RBC also noted that the drug's tolerability profile lagged that of zoldon, although it viewed the safety profile as manageable.</p><p>RBC raised its price target on Verastem to $19 from $14, with an outperform rating.</p><p>The company's shares were up nearly 6% in Thursday afternoon trading.</p><p>Price: 8.16, Change: +0.45, Percent Change: +5.84</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VSTM","symbol_name":"Verastem","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2675153916","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2675153916","pubTimestamp":1792081640,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Verastem's  G12D drug showed promising efficacy in pancreatic cancer, while its shares remain undervalued, RBC Capital Markets said in a note Thursday.The analysts said the company presented new research and development results for its G12D drug at an R&D day. The drug appears to be active, with early signs that it could deliver strong efficacy in treating pancreatic cancer.More data is needed to determine whether the drug offers meaningful advantages over competing G12D treatments. However, RBC believes the company has outlined a strategy to target a niche in the US market and that its shares do not fully reflect the potential value of its pipeline and Av-Fak business.The analysts said VS-7375's efficacy data were encouraging, with a confirmed response rate of 41% in pancreatic cancer. However, they cautioned that comparisons with competing drugs are complicated by small patient numbers and differences between trial populations. RBC also noted that the drug's tolerability profile lagg","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VSTM":"Verastem","BK4139":"生物科技"},"translate_title":"加拿大皇家银行表示，Verastem 的 G12D 药物在胰腺癌方面显示出前景，但股价被低估","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VSTM":1.5},"content_text":"Verastem's (VSTM) G12D drug showed promising efficacy in pancreatic cancer, while its shares remain undervalued, RBC Capital Markets said in a note Thursday.The analysts said the company presented new research and development results for its G12D drug at an R&D day. The drug appears to be active, with early signs that it could deliver strong efficacy in treating pancreatic cancer.More data is needed to determine whether the drug offers meaningful advantages over competing G12D treatments. However, RBC believes the company has outlined a strategy to target a niche in the US market and that its shares do not fully reflect the potential value of its pipeline and Av-Fak business.The analysts said VS-7375's efficacy data were encouraging, with a confirmed response rate of 41% in pancreatic cancer. However, they cautioned that comparisons with competing drugs are complicated by small patient numbers and differences between trial populations. RBC also noted that the drug's tolerability profile lagged that of zoldon, although it viewed the safety profile as manageable.RBC raised its price target on Verastem to $19 from $14, with an outperform rating.The company's shares were up nearly 6% in Thursday afternoon trading.Price: 8.16, Change: +0.45, Percent Change: +5.84","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2675153916","isCrawlerRequest":true}